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1 Introduction
In December 2000 the Unilever Centre for Molecular Sci-
ence Informatics (UCMSI) was opened at the Department of
Chemistry of University of Cambridge. Based on an invest-
ment by the industrial partner Unilever, a new world-lead-
ing research group in the emerging field of molecular infor-
matics was established. The investment included a new
building, an established chair in Molecular Science Infor-
matics and three lectureships as well as set up costs (equip-
ment, networking, and software). The Unilever research
grants were renewed in year five and year ten. In addition,
over the period of the UCMSI’s existence, significant addi-
tional grants from a variety of industrial, charitable and re-
search council sources were obtained to support the objec-
tives of the UCMSI.
The research centre is located in central Cambridge, thus
profiting from a stimulating and exciting research environ-
ment. Daily interactions with several other local institutes
at the University of Cambridge, the EMBL European Bioin-
formatics Institute (EBI), and the Cambridge Crystallograph-
ic Data Centre (CCDC) create a world class research cluster.
Furthermore, several major industrial partners are located
in close proximity in Cambridge’s science parks and on cor-
porate research sites.
Collaborations with more than twenty industrial partners
and especially Unilever allowed access to high quality data
sets and formed the basis for state-of-the-art computational
modelling.[1] Further industrial partners have included Boeh-
ringer Ingelheim, AstraZeneca, BASF, Pfizer, Johnson&John-
son, GSK, Aboca and Eli Lilly, to name but a few. Additional
third party funding was attracted at the national level from
the UK Engineering and Physical Sciences Research Council,
The Medical Research Council, The Wellcome Trust, and the
Biotechnology and Biological Sciences Research Council, as
well as The National Institutes of Health in the USA. On the
European level, major grants from the European Chemical
Industry Council (CEFIC) and the European Research Coun-
cil (ERC), and the Framework-7 program were successfully
obtained, funding a variety of international informatics re-
search projects.
The research at the UCMSI covers broad areas of chemin-
formatics, which coupled with experiments and collabora-
tions with industrial partners in bringing products to the
market, ensures real life feedback in several inter-disciplina-
ry research efforts. A main goal of the currently 40 scien-
tists in the UCMSI is the integration of chemistry, biology
and materials science through the development and appli-
cation of molecular informatics. Robert Glen has directed
the UCMSI since its opening. He heads an interdisciplinary
research group using a broad set of computational meth-
odologies to tackle basic scientific questions in the general
area of molecular biosystems. Four additional research
groups are focusing on relevant areas on cheminformatics
research at the UCMSI. The group of Jonathan Goodman
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focuses on synthesis, computation and informatics and ap-
plies cheminformatics to tackle questions in chemical reac-
tivity and catalysis. Peter Murray-Rust’s group focuses on
semantic web technologies and develops methodologies
and software for intelligent storage and retrieval of chemi-
cal data. Andreas Bender’s group drives the integration of
new large scale data sources (gene expression, biological
networks, phylogenetics) in the field of cheminformatics.
Recently, Lucy Colwell has established a new group at the
Centre, her research aims to identify structural features
within large datasets using advanced statistical and data
analytics methodologies. Two former group leaders have
recently departed from the UCMSI to set up significant re-
search groups. Peter J. Bond recently moved on to a princi-
pal investigator position at the Bioinformatics (BII) Institute
A*STAR in Singapore and continues his research efforts on
multiscale modelling and large scale simulations. Former
group leader John Mitchell has moved to the University of
St. Andrews as a Reader and continues broad research in
cheminformatics from quantum chemistry to molecular
simulation technologies. Former group leaders include
David Lary, Guy Grant, Dmitry Nerukh, Maxim Federov and
Hamse Mussa.
Over the years of the Centre’s existence 67 PhDs have
been trained and 36 postdoctoral research associates per-
formed high quality research. The UCMSI hosted 50 confer-
ences/workshops and organized over 200 seminars. Scien-
tists at the UCMSI have won several awards and prizes in-
cluding the RSC Bader Award to Jonathan Goodman, the
Hansch Award to Andreas Bender, and the Novartis Chemis-
try Lectureship to Robert Glen. In this article we describe
the developments in cheminformatics research performed
at the UCMSI aiming to identify challenges and opportuni-
ties for the field in the future.
2 Methods
2.1 Data Mining in Web of Science
We retrieved all entries related to the UCMSI in all Web of
Science databases.[2] Therefore, we used the Web of Science
web interface and extracted entries with at least one au-
thors address containing all words “Cambridge”, “Universi-
ty”, “Molecular”, and “Unilever”. Furthermore, we discarded
entries in the database earlier than the year 2001, to
remove three false positive hits of earlier years. Unfortu-
nately, some entries (e.g.[3,4]) are discarded as false nega-
tives at this stage, as different abbreviations in author affili-
ations have been used. Citing articles and total citations
were extracted for all articles and analyzed in terms of self-
and non-self citations according to the tools provided in
the Web of Science online mask. The Hirsch index (h-
index)[5] was calculated to estimate a total impact of the
science performed at the UCMSI.
2.2 Analysis of Publications Using Word Clouds
Furthermore, we extracted information on author names
and abstracts (where available) from all publications. We
identified the leading scientists and their central research
topics using word cloud representations (“wordles”) gener-
ated using WordItOut.[6] We used author surnames only to
ensure consistency between different data sources. Full ab-
stracts were used for the generation of topic-related word
clouds. To allow for identification of trends over time we
split the complete data sets for authors and abstracts into
sections of years. Thereby, we analyzed author and themat-
ic contributions for the years 2001–2004, 2005–2007, 2008–
2010, and 2011–2014 respectively.
3 Results
We identified in total 325 published items of the UCMSI in
the Web of Science database. After an initial growth phase,
the article output has reached a stable plateau of between
twenty and 40 published items per year (see Figure 1A).
The observed decrease for the year 2014 arises from incom-
plete data for the current year. Linear extrapolation to the
complete year increases the number of published articles
listed in Web of Science to the average level of approxi-
mately 20. Due to lagging indexing in Web of Science
linear extrapolation is expected to underestimate values for
year 2014. When setting aside the incomplete year 2014,
Pearson correlation between years and published items is
0.78, indicating a steadily growing output of research per-
formed at the Centre.
In addition to the number of published items, citations
were counted on articles published by the Centre. Soon
after publication of the first two articles in 2001, first cita-
tions are recorded (see Figure 1B). The amount of citations
continues to grow steadily over the years and breaks the
barrier of 100 citations in the year 2005. Results are shown
on a per-year basis, not as a cumulative count. Neverthe-
less, an almost linear increase of citations with Pearson cor-
relation coefficient of 0.97 between year and citations is
observed when excluding the incomplete year 2014. With
988 citations in the year 2013 only, research from the
UCMSI is referenced almost three times per day. Linear ex-
trapolation for year 2014 indicates that the barrier of 1000
citations is likely to be broken for the first time.
In total 5508 citations on the 325 articles were recorded
via Web of Science. Only nine percent of these represent
self-citations (506 citations), thus reflecting a broad audi-
ence and considerable impact within the cheminformatics
community. 4109 unique indexed articles reference scientif-
ic reports from the UCMSI with less than five percent of
self-citations (177 articles). On average, articles from the
Centre are cited 16.95 times.
No single article accounts for the large average citation
count. By contrast, eight articles are individually cited over
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100 times, all of them have been published in 2004 or
later.[7–14] This broad impact is reflected by an h-index of 39
after 14 years of existence of the Centre. Eight articles are
indicated as “highly cited articles” within Web of Sci-
ence,[9,11–13,15–18] thus representing the top one percent pub-
lications in the respective field. These articles only partially
overlap with articles already cited more than 100 times.
This indicates that they will most likely be the next ones
crossing the barrier of 100 citations.
By creating word clouds from author lists of all published
items we identified key scientists at the UCMSI in Cam-
bridge (see Figure 2A). Robert C. Glen has published 83
items over the years, closely followed by the group leaders
Peter Murray-Rust, Andreas Bender, and Jonathan Good-
man, each contributing between 60 and 70 articles. Split-
ting author contributions according to intervals of years
allows the development of the UCMSI to be followed. In
earlier years, lecturer John Mitchell was a highly active re-
searcher at the UCMSI, as was Henry Rzepa in collaboration
with Peter Murray-Rust (see Figure 2B). In later years the
name “Andreas Bender” emerges more and more with
a short break during his time at Novartis and the University
of Leiden (see Figure 2C and Figure 2D). In recent years,
the group of Peter Bond focusing on simulations added ad-
ditional output to the UCMSI (see Figure 2E).
Wordles created on the basis of published abstracts iden-
tify key topics and methods applied at the UCMSI (see Fig-
ure 3A). “Data” is the most abundant single phrase and ap-
pears mostly in connection with the second most occurring
words “molecular” and “chemical”. Therefore, chemical data
form the foundation of all research performed at the
Centre. “Model” and “models” appear prominent in the list,
giving hints how chemical data is utilized in the generation
of computational models for a variety of mostly chemical
and biological properties.
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Figure 1. Scientific publications at the UCMSI: A) Published items at the UCMSI are shown over the years of its existence since 2000. An in-
crease to a stable plateau of around two publications per month is visible. B) Citations related to items published at the UCMSI. The in-
creasing importance of research performed in the field of cheminformatics is reflected by steadily growing citations per year.
Figure 2. Word clouds of co-authors listed on publications of the UCMSI: A) Word cloud over all years of existence. B–E) Author occurrenc-
es are split according to years 2004–2004, 2005–2007, 2008–2010, and 2011–2014 respectively.
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Splitting abstracts according to publication years does
not reveal any consistency in the research efforts on-going
at the UCMSI (see Figures 3B–3E). Contributions of “molecu-
lar” and “data” are constantly high. Some words linked to
the observables predicted in established models appear
transiently, e.g. “target” for recently established target pre-
diction tools. Nevertheless, the low frequency of individual
modelled molecular properties reflects the broadness of
topics covered. Furthermore, structure-based modelling ap-
proaches[19] appear more prominent in recent years as indi-
cated by the increasing occurrence of the keywords “pro-
tein”, “water”, and “dynamics”.
4 Discussion
Analysis of citations has allowed the identification of key
topics and methods applied at the UCMSI. Science is often
centred around method development which is reflected by
several publications in leading journals in the field of chem-
informatics and modelling. Additionally, application of the
newly developed methods ensures real life feedback and
enabled publications in fields ranging from drug discovery
to synthesis, materials science to electrochemistry. In the
following paragraphs we will select particular fields of re-
search where major advances have been made at the
Centre.
4.1 Linking Cheminformatics and Biology
Starting from innovative ways to encode and compare
chemical environments in molecules,[7,8,10] several steps
have been taken to link chemical with biological properties
of molecules[20] based on statistical modelling tech-
niques.[21,22] Thereby, the fields of cheminformatics and bio-
informatics increasingly overlap and even fuse, leading to
approaches like proteochemometric modelling (PCM).[23,24]
With the establishment of target prediction tools based on
statistical modelling,[25,26] novel approaches to cluster mole-
cules using predicted biological effect can be implement-
ed.[27] Furthermore, these novel methodologies proved to
be helpful in multi target drug design.[28] Recent directions
in the area comprise the inclusion of further biological data
sources, e.g. from biological networks and phylogenet-
ics[29,30] as well as gene expression data.[31] Several success-
ful applications of target prediction algorithms[32–34] under-
line the increasing accuracy of such data-driven approaches
and point towards a bright future given the increase in
available data sources.[35,36] In a recent success story chem-
informatic tools were applied to identify potential targets
of a series of synthetic biscoumarins showing anti-cancer
activity in vitro and in vivo.[37] After in depth computational
characterization of predicted protein-ligand interactions
(see Figure 4A), the in silico predicted protein target
tumour necrosis factor a was verified by experimental tech-
niques. An emerging future direction in this field is the pre-
diction of biological effects of compound combinations
that is financed via an ERC Starting Grant to Andreas
Bender. Further stimuli in this area expected from statistical
analyses of genomic sequence data.[38,39]
4.2 Data Semantics and Accessibility
Growth of the available (“Big”) data brings new challenges
to the field of cheminformatics. Millions of chemical sub-
stances have been characterized, many hundreds of thou-
sands of three-dimensional structures have been deposited
in databases, and associated biological data is spread over
millions of publications and patents.[40] Therefore, the de-
velopment of standards for chemical identification, index-
ing and storage is crucial for future successful data retriev-
al. Usage of the IUPAC standard International Chemical
Identifiers (InChIs) allows the encoding of chemical infor-
mation using a unique text descriptor, e.g. for database
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Figure 3. Wordles generated from indexed abstracts of publications from the UCMSI: A) Word cloud over all years of existence of the
Centre. B-E) Word occurrences are analysed in terms of chronological development over the years 2001–2004, 2005–2007, 2008–2010, and
20011–2014.
 0000 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim Mol. Inf. 0000, 00, 1 – 9 &4&
These are not the final page numbers! 
Full Paper www.molinf.com
searches.[41] Based on InChIs several tools have been devel-
oped, e.g. to convert structures to chemical names in
a fully automated way[42] or chemistry-aware text mining.[43]
Recently, InChIs have been extended to RinChIs to depict
chemical reactions unambiguously.[44] Chemical Markup
Language (CML) introduces and specifies particular data
fields to efficiently store and retrieve chemical data.[45]
Based on CML the World-Wide Molecular Matrix (WWMM)
has been introduced to collect and connect chemical infor-
mation of various sources.[46] Chem4Word has been created
in a collaboration between Microsoft Research and the
UCMSI to facilitate the handling of chemical information
within text processing software. To date, the plug-in has
been downloaded more than 400 000 times. Over the last
decade, the UCMSI has been a key player in setting stand-
ards for open data and data quality standards in chemis-
try.[47–49] In recent years, technologies for data semantics
and natural language processing have been employed at-
tempting to directly extract the scientific context of pub-
lished chemical data.[50]
4.3 Modelling of Physicochemical Properties and ADMET
Parameters
The increase in data sources over recent years allowed the
establishment of more accurate computational models,
even for complex biological phenomena, e.g. absorption,
distribution, metabolism, excretion and toxicity (ADMET) of
xenobiotics.[51] Dozens of computational methods for pre-
diction of metabolic reactions on different levels of com-
plexity have been published in the literature.[16] Thorough
classification of annotated biotransformations[52] facilitated
the development of novel predictive models for general
metabolic reactivity (Metaprint2D),[53,54] P-glycoprotein
transport,[55] solubility,[56] and cytochrome P450-catalyzed
metabolic reactions.[57–59] Thereby, innovative computational
methods making use of recent advances in graphics proc-
essing unit (GPU) based computing have been employed.
Using these approaches, new levels of throughput and
thus modelling accuracy are in range. Furthermore, the
UCMSI ran a solubility competition (with over 100 entries)
for the cheminformatics community and provided high
quality experimental data to facilitate further method de-
velopments in the area.[60–62]
4.4 Bioactive Compound Discovery
The UCMSI has been a driving force of computer-aided
drug design over the past decades. In addition to support
of external drug design efforts, local lead discovery projects
have been guided by computational technologies. Novel li-
gands for the G-protein coupled receptor (GPCR) apelin
have been successfully identified and biologically character-
ized.[63] Based on modelled structures of the apelin receptor
(see Figure 4B), optimization of the peptide-derived com-
pounds is on-going and shows enormous potential for fur-
ther development and recently the first human study of
apelin biased agonists has been completed in Adden-
brooke’s hospital in Cambridge. (Design, characterization
and first-in-human study of the vascular actions of a novel
‘biased’ apelin receptor agonist. Anthony Davenport, Aimee
Brame, Janet Maguire, Peiran Yang, Alex Dyson, Rubben
Torella, Joseph Cheriyan, Mervyn Singer, Robert Glen, Ian
Wilkinson. Hypertension, in press, 2015). Furthermore, small
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Figure 4. Examples of cheminformatics research currently performed at the UCMSI: A) Ensemble of protein-ligand poses extracted from
a molecular dynamics simulation of tumor necrosis factor a (TNFa, green cartoon) in complex with a biscoumarin (cyan sticks). The native
trimeric structure of TNFa (semi-transparent yellow cartoon, PDB: 1TNF) is disrupted by ligand binding. A zoom on the binding site high-
lights the hydrophobic environment of the ligand, allowing for several binding modes. B) Model of the apelin receptor (green cartoon) in
complex with the apelin-13 peptide (cyan sticks). Starting coordinates of a molecular dynamics simulation box are depicted including
a model lipid bi-layer (yellow lines and semi-transparent surface) along with explicit water molecules and counter ions (both not shown).
The predicted binding mode of the apelin-13 peptide and surrounding residues are highlighted in the included zoom on the binding
cavity. C) Illustration of the simulation approach followed to investigate selectivity of Schiff base forming covalent IRE-1 inhibitors. IRE-1 is
shown as cartoon with the reactants Lys-907 and inhibitor 4m8C highlighted as sticks.
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molecule antagonists of the 5-HT1B GPCR have been iden-
tified and optimized for development as a potential treat-
ment for Pulmonary Hypertension.[64] Several newly de-
signed and synthesized compounds are currently in clinical
studies in Addenbrooke’s Hosptial, Cambridge. In another
compound discovery effort large scale simulation ap-
proaches (see Figure 4C) have been used to identify cova-
lent binders of the endonuclease domain of IRE-1.[65,66] In
a follow-up study selectivity of the Schiff base forming
compounds has been investigated by advanced computa-
tional techniques.[67] Research at the UCMSI also lead to
joint patents with Unilever on the CB1/2 receptors and
NCKX ion channels showing benefits in skin for use in
home and personal care products. To assist drug discovery
several analyses of molecular diversity in the context of di-
versity-oriented chemical synthesis have been performed in
collaboration with experimental groups.[68–70]
In addition to these four areas the UCMSI has been par-
ticularly active in development of innovative simulation
and analysis methodologies[71,72] and cheminformatic sup-
port for organic synthesis.[73,74] Industrial partners empha-
size the productivity of collaborative research efforts with
the Centre for Molecular Informatics. Ola Engkvist, team
leader of Computational Chemistry at AstraZeneca and in-
volved in several joint research projects, highlights: “The
collaboration with the UCMSI provides AstraZeneca with
the opportunity to work closely with one of the world lead-
ing groups in cheminformatics. The combination of the
UCMSI’s outstanding scientific knowledge with AstraZene-
ca’s industrial experience provides a platform for state-of-
the-art research in cheminformatics. The proximity to one
of the AstraZeneca science hubs is an additional plus that
facilitates smooth collaborations.” Jim Crilly, senior vice-
president of the Strategic Science Group at Unilever, adds:
“Unilever is very proud to have instigated in partnership
with the University of Cambridge the Centre for Molecular
Informatics under the Leadership of Professor Robert Glen
and pleased that it has developed into a global centre of
excellence in a hugely important field of research. Collabo-
ration with the centre has brought a new way of working
into our own research endeavours and accelerated our dis-
covery process.”
Following a clear mission statement published in 2002[75]
the UCMSI is developing tools and standards in molecular
informatics. With the increase in computer power and data
accessibility, molecular modelling allows chemical and bio-
logical effects of increasing complexity and size to be cap-
tured. Available data sources range from chemistry and re-
lated bioactivity (PubChem,[76] ChEMBL,[35] DrugBank[77]) via
protein sequence (UniProt[78]) and structure (Protein Data
Bank,[79] Pfam[80]), to cellular pathways (KEGG[81]) and re-
sponses (LINCS[82]). A collection of online molecular biology
databases has recently been published with the database
issue of Nucleic Acids Research.[83]
With the advent of microsecond simulations of biological
macromolecules[84] and sophisticated enhanced sampling
methods,[85] dynamic processes underlying macromolecular
recognition processes can be modelled with a new level of
accuracy.[86] Protein-ligand binding processes may be stud-
ied at atomistic resolution, reports include full sampling of
binding and unbinding of both fragments[87] and small mol-
ecules.[88] With an increasingly accurate description of pro-
tein dynamics, its role in biomolecular recognition process-
es can be studied, thereby allowing pharmaceutically rele-
vant properties like binding specificity[89] or binding kinet-
ics[90] including allosteric mechanisms[91] to be probed. On
the other hand, integration of innovative data sources from
emerging “omics” fields such as proteomics,[92] metabo-
nomics/metabolomics,[93] or lipidomics[94] will allow the cap-
ture of novel biological properties which have limited or no
direct chemical leads to their mechanism and function.
5 Conclusions
The data presented underline the central role in the chem-
informatics world that is occupied by the UCMSI. The re-
search institute sets world-wide standards and publishes
technologies and software that is widely used and cited.
The broad range of topics covered at the UCMSI ensures its
broad impact ranging from basic cheminformatics, data
mining and machine learning techniques to complex simu-
lations, to chemical reactivity and synthesis. The connection
of all these areas in a single research centre offers unique
opportunities for scientists involved, industrial partners, as
well as the whole cheminformatics community.
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